Robert Fontana, MD
Gastroenterology · Ann Arbor, MINPI 1700968237
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,895 of the $15,929 with a category attached, or 99.8%. 5 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 43.2% of the total. 2025 is the largest year on record at $6,922, 2.1 times the $3,232 reported in 2019.
Across 7 payments — averaging $2275.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$7K
- Modernatx, Inc.$5K
- Astrazeneca UK Limited$3K
- Sanofi US Services Inc.$750
- Novo Nordisk$34
Across 108 payments — averaging $2324.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$177K
- Gilead$65K
- Sanofi US Services Inc.$6K
- Bioverativ Therapeutics Inc.$2K
- Inova Diagnostics, Inc.$620
What the payments were for
- Consulting fees$15,895100%
- Food & beverage$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 2 | $6,888 |
| Modernatx, Inc. | 1 | $5,025 |
| Astrazeneca UK Limited | 2 | $3,232 |
| Sanofi US Services Inc. | 1 | $750 |
| Novo Nordisk | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$6,888
How this compares
$15,929 in reported general payments places this provider in the 85th percentile of 497 gastroenterology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 60 | $190,214 |
| VemlidyTenofovir Alafenamide | 32 | $47,096 |
| Tacrolimus | 225 | $39,963 |
| EliquisApixaban | 31 | $39,388 |
| Ursodiol | 109 | $19,627 |
| Envarsus XrTacrolimus | 19 | $15,637 |
| XareltoRivaroxaban | 16 | $13,278 |
| Cyclosporine ModifiedCyclosporine, Modified | 59 | $12,252 |
| Mycophenolate Mofetil | 71 | $7,541 |
| Enoxaparin Sodium | 17 | $6,852 |
| Entecavir | 38 | $2,921 |
| Azathioprine | 55 | $2,573 |
| Lactulose | 34 | $2,253 |
| Omeprazole | 72 | $1,376 |
| Prednisone | 98 | $1,073 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Ann Arbor
- Philip SchoenfeldAnn Arbor$539K
- Michelle Muza-MoonsAnn Arbor$481K
- Allison SchulmanAnn Arbor$124K
- Eric ShahAnn Arbor$120K
- Peter HigginsAnn Arbor$111K
- Neehar ParikhAnn Arbor$101K
- William CheyAnn Arbor$90K
- Ryan StidhamAnn Arbor$83K
- Elliot TapperAnn Arbor$69K
- Michael RiceAnn Arbor$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.